RT Journal Article SR Electronic T1 Burden and Risk Factors for Pseudomonas aeruginosa Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 1701190 DO 10.1183/13993003.01190-2017 A1 Marcos I. Restrepo A1 Bettina L. Babu A1 Luis F. Reyes A1 James D. Chalmers A1 Nilam J. Soni A1 Oriol Sibila A1 Paola Faverio A1 Catia Cilloniz A1 William Rodriguez-Cintron A1 Stefano Aliberti YR 2018 UL http://erj.ersjournals.com/content/early/2018/06/07/13993003.01190-2017.abstract AB Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic antibiotic resistance to the most frequently used antibiotics in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP.We enrolled 3,193 patients in 54 countries with confirmed diagnosis of CAP that underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP.The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases [i.e., tracheostomy, bronchiectasis and/or very severe COPD]) was 67%. In contrast, the rate of P. aeruginosa CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases.The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Restrepo has nothing to disclose.Conflict of interest: Ms. Babu has nothing to disclose.Conflict of interest: Dr. Reyes has nothing to disclose.Conflict of interest: Dr. Chalmers reports grants and personal fees from Glaxosmithkline, grants and personal fees from Boehringer-Ingelheim, grants from Astrazeneca, grants and personal fees from Pfizer, grants and personal fees from Bayer Healthcare, grants and personal fees from Grifols, personal fees from Napp, outside the submitted work.Conflict of interest: Dr. Soni has nothing to disclose.Conflict of interest: Dr. Sibila has nothing to disclose.Conflict of interest: Dr. Faverio has nothing to disclose.Conflict of interest: Dr. Cilloniz has nothing to disclose.Conflict of interest: Prof. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work; .Dr. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work; .Dr. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work.Conflict of interest: Dr. Rodriguez Cintron has nothing to disclose.